Quote | Super Quote
14325 MB-CSPC@EC2201A (CALL)
RT Nominal unchange0.027 0.000 (0.000%)

03/09/2021 10:36

CSPC Pharma (01093) gets clinical trial approval

[ET Net News Agency, 3 September 2021] CSPC Pharmaceutical Group Limited (01093) said
Shanghai Novarock Biopharmaceutical Co., Ltd., a subsidiary of the company, has obtained
approval granted by the National Medical Products Administration of the People's Republic
of China to conduct clinical trial for NBL-015 in China.
NBL-015 is a fully human anti-Claudin 18.2 monoclonal antibody discovered and developed
by NovaRock Biotherapeutics Limited, a subsidiary of the company, for treating advanced
solid tumours with positive Claudin 18.2 expression, including pancreatic cancer and
gastric cancer (including cancer of the gastroesophageal junction). The Phase I clinical
trials will evaluate the safety, tolerability and pharmacokinetics of NBL-015 in patients
with advanced solid tumours. (RC)

Remark: Real time quote last updated: 30/11/2021 17:59
  Real-time basic market prices of Hong Kong securities are provided by HKEx; a Designated Website authorized by the HKEx Group to provide the Service
A Member of HKET Holdings
Customer Service Hotline:(852) 2880 7004     Customer Service Email:cs@etnet.com.hk
Copyright 2021 ET Net Limited. http://www.etnet.com.hk ET Net Limited, HKEx Information Services Limited, its Holding Companies and/or any Subsidiaries of such holding companies, and Third Party Information Providers endeavour to ensure the availability, completeness, timeliness, accuracy and reliability of the information provided but do not guarantee its availability, completeness, timeliness, accuracy or reliability and accept no liability (whether in tort or contract or otherwise) any loss or damage arising directly or indirectly from any inaccuracies, interruption, incompleteness, delay, omissions, or any decision made or action taken by you or any third party in reliance upon the information provided. The quotes, charts, commentaries and buy/sell ratings on this website should be used as references only with your own discretion. ET Net Limited is not soliciting any subscriber or site visitor to execute any trade. Any trades executed following the commentaries and buy/sell ratings on this website are taken at your own risk for your own account.